Karo Bio Announces Successful Phase II Study With Eprotirome In Combination With Statin

�Karo Bio has successfully completed a 12 calendar week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on lipid-lowering medication treatment. Data show that eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein (a) and was safe and well tolerated. The data indicate that eprotirome has the